• 1
    Gotuzzo E., Seas C., Guerra J.G., Carrillo C., Bocanegra T.S., Calvo A., Castaneda O., Alarcon G.S. (1987) Brucellar arthritis: a study of 39 Peruvian families. Ann Rheum Dis 46: 506509.
  • 2
    Corbel M.J. (1997) Recent advances in brucellosis. J Med Microbiol 46: 101103.
  • 3
    Godfroid J., Cloeckaert A., Liautard J.P., Kohler S., Fretin D., Walravens K., Garin-Bastuji B., Letesson J.J. (2005) From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis. Vet Res 36: 31326.
  • 4
    Golding B., Scott D.E., Scharf O., Huang L-Y., Zaitseva M., Lapham C., Eller N., Golding H. (2001) Immunity and protection against Brucella abortus. Microbes Infect 3: 438.
  • 5
    Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikova L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., Molina P.E., Abumrad N.N., Sama A., Tracey K.J. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 24851.
  • 6
    Droste A., Sorg C., Hogger P. (1999) Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. Biochem Biophys Res Commun 256: 1103.
  • 7
    Weaver L.K., Pioli P.A., Wardwell K., Vogel S.N., Guyre P.M. (2007) Up-regulation of human monocyte CD163 upon activation of cell-surface Toll-like receptors. J Leukoc Biol 81: 66371.
  • 8
    Stros M. (2010) HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta 1799: 10113.
  • 9
    Weir H.M., Kraulis P.J., Hill C.S., Raine A.R., Laue E.D., Thomas J.O. (1993) Structure of the HMG box motif in the B-domain of HMG1. EMBO J 12: 13119.
  • 10
    Li J., Kokkola R., Tabibzadeh S., Yang R., Ochani M., Qiang X., Harris H.E., Czura C.J., Wang H., Ulloa L., Wang H., Warren H.S., Moldawer L.L., Fink M.P., Andersson U., Tracey K.J., Yang H. (2003) Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 9: 3745.
  • 11
    Yang H., Ochani M., Li J., Qiang X., Tanovic M., Harris H.E., Susarla S.M., Ulloa L., Wang H., DiRaimo R., Czura C.J., Wang H., Roth J., Warren H.S., Fink M.P., Fenton M.J., Andersson U., Tracey K.J. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101: 296301.
  • 12
    Andersson U., Wang H., Palmblad K., Aveberger A.C., Bloom O., Erlandsson-Harris H., Janson A., Kokkola R., Zhang M., Yang H., Tracey K.J. (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192: 56570.
  • 13
    Yang H., Tracey K.J. (2009) Targeting HMGB1 in inflammation. Biochim Biophys Acta 1799: 14956.
  • 14
    Bianchi M.E. (2009) HMGB1 loves company. J Leukoc Biol 86: 5736.
  • 15
    Kristiansen M., Graversen J.H., Jacobsen C., Sonne O., Hoffman H.J., Law S.K., Moestrup S.K. (2001) Identification of the haemoglobin scavenger receptor. Nature 409: 198201.
  • 16
    Moller H.J., Aerts H., Gronbaek H., Peterslund N.A., Hyltoft Petersen P., Hornung N., Rejnmark L., Jabbarpour E., Moestrup S.K. (2002) Soluble C D163: a marker molecule for monocyte/macrophage activity in disease. Scand J Clin Lab Invest Suppl 237: 2933.
  • 17
    Maniecki M.B., Moller H.J., Moestrup S.K., Moller B.K. (2006) CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. Immunobiology 211: 40717.
  • 18
    Sulahian T.H., Hintz K.A., Wardwell K., Guyre P.M. (2001) Development of an ELISA to measure soluble CD163 in biological fluids. J Immunol Methods 252: 2531.
  • 19
    Moller H.J., Peterslund N.A., Graversen J.H., Moestrup S.K. (2002) Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 99: 37880.
  • 20
    Moestrup S.K., Moller H.J. (2004) CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 36: 34754.
  • 21
    Araya L.N., Elzer P.H., Rowe G.E., Enright F.M., Winter A.J. (1989) Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus. J Immunol 143: 333037.
  • 22
    Ko J., Splitter G.A. (2003) Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans. Clin Microbiol Rev 16: 6578.
  • 23
    Akbulut H.H., Kilic S.S., Bulut V., Ozden M. (2005) Determination of intracellular cytokines produced by Th1 and Th2 cells using flow cytometry in patients with brucellosis. FEMS Immunol Med Microbiol 45: 2538.
  • 24
    Akbulut H., Celik I., Akbulut A. (2007) Cytokine concentrations in patients with brucellosis and their relations with the treatment. Indian J Med Microbiol 25: 38790.
  • 25
    Fernandes D.M., Baldwin C.L. (1995) Interleukin-10 downregulates protective immunity to Brucella abortus. Infect Immun 63: 11303.
  • 26
    Galanakis E., Makis A., Bourantas K.L., Papadopoulou Z.L. (2002) Interleukin-3 and interleukin-4 in childhood brucellosis. Infection 30: 334.
  • 27
    Rodriguez-Zapata M., Matias M.J., Prieto A., Jonde M.A., Monserrat J., Sanchez L., Reyes E., De la Hera A., Alvarez-Mon M. (2010) Human brucellosis is characterized by an intense Th1 profile associated with a defective monocyte function. Infect Immun 78: 32729.
  • 28
    Gordon S. (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 2335.
  • 29
    Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 67786.
  • 30
    Mosser D.M. (2003) The many faces of macrophage activation. J Leukoc Biol 73: 20912.
  • 31
    Gordon S., Martinez F.O. (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32: 593604.
  • 32
    Fiuza C., Bustin M., Talwar S., Tropea M., Gerstenberger E., Shelhamer J.H., Suffredini A.F. (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101: 265260.
  • 33
    Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 54955.
  • 34
    Gardella S., Andrei C., Ferrera D., Lotti L.V., Torrisi M.R., Bianchi M.E., Rubartelli A. (2002) The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 3: 9951001.
  • 35
    Kokkola R., Sundberg E., Ulfgren A.K., Palmblad K., Li J., Wang H., Ulloa L., Yang H., Yan X.J., Furie R., Chiorazzi N., Tracey K.J., Andersson U., Harris H.E. (2002) High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum 46: 2598603.
  • 36
    Yu M., Wang H., Ding A., Golenbock D.T., Latz E., Czura C.J., Fenton M.J., Tracey K.J., Yang H. (2006) HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26: 1749.
  • 37
    Tsung A., Sahai R., Tanaka H., Nakao A., Fink M.P., Lotze M.T., Yang H., Li J., Tracey K.J., Geller D.A., Billiar T.R. (2005) The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201: 113543.
  • 38
    Rauvala H., Rouhiainen A. (2010) Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors. Biochim Biophys Acta 1799: 16470.
  • 39
    Fabriek B.O., van Bruggen R., Deng D.M., Ligtenberg A.J., Nazmi K., Schornagel K., Vloet R.P., Dijkstra C.D., van den Berg T.K. (2009) The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood 113: 88792.
  • 40
    Goldstein J.I., Goldstein K.A., Wardwell K., Fahrner S.L., Goonan K.E., Cheney M.D., Yeager M.P., Guyre P.M. (2003) Increase in plasma and surface CD163 concentrations in patients undergoing coronary artery bypass graft surgery. Atherosclerosis 170: 32532.
  • 41
    Knudsen T.B., Gustafson P., Kronborg G., Kristiansen T.B., Moestrup S.K., Nielsen J.O., Gomes V., Aaby P., Lisse I., Moller H.J., Eugen-Olsen J. (2005) Predictive value of soluble haemoglobin scavenger receptor CD163 serum concentrations for survival in verified tuberculosis patients. Clin Microbiol Infect 11: 7305.
  • 42
    Gaini S., Pedersen S.S., Koldkjaer O.G., Pedersen C., Moller H.J. (2007) High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study. Crit Care 11: R32.
  • 43
    Gaini S., Koldkjaer O.G., Moller H.J., Pedersen C., Pedersen S.S. (2007) A comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: a prospective study. Crit Care 11: R76.
  • 44
    Sunden-Cullberg J., Norrby-Teglund A., Rouhiainen A., Rauvala H., Herman G., Tracey K.J., Lee M.L., Andersson J., Tokics L., Treutiger C.J. (2005) Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33: 56473.
  • 45
    Yasuda T., Ueda T., Takeyama Y., Shinzeki M., Sawa H., Nakajima T., Ajiki T., Fujino Y., Suzuki Y., Kuroda Y. (2006) Significant increase of serum high-mobility group box chromosomal protein 1 concentrations in patients with severe acute pancreatitis. Pancreas 33: 35963.
  • 46
    Angus D.C., Yang L., Kong L., Kellum J.A., Delude R.L., Tracey K.J., Weissfeld L. (2007) Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 35: 10617.
  • 47
    Gibot S., Massin F., Cravoisy A., Barraud D., Nace L., Levy B., Bollaert P.E. (2007) High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med 33: 134753.
  • 48
    Gaini S., Pedersen S.S., Koldkjaer O.G., Pedersen C., Moestrup S.K., Moller H.J. (2008) New immunological serum markers in bacteraemia: anti-inflammatory soluble CD163, but not proinflammatory high mobility group-box 1 protein, is related to prognosis. Clin Exp Immunol 151: 42331.
  • 49
    Feighery C., Dunne J., Bingham E.A., Feighery C.F. (2010) Evaluation of soluble CD163 as a marker of inflammation in psoriasis. Clin Exp Dermatol 36: 201203.
  • 50
    Moller H.J., Moestrup S.K., Weis N., Wejse C., Nielsen H., Pedersen S.S., Attermann J., Nexo E., Kronborg G. (2006) Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. Crit Care Med 34: 25616.
  • 51
    Wang H., Yang H., Czura C.J., Sama A.E., Tracey K.J. (2001) HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 164: 176873.
  • 52
    Ueno H., Matsuda T., Hashimoto S., Amaya F., Kitamura Y., Tanaka M., Kobayashi A., Maruyama I., Yamada S., Hasegawa N., Soejima J., Koh H., Ishizaka A. (2004) Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 170: 131016.
  • 53
    Barnay-Verdier S., Fattoum L., Borde C., Kaveri S., Gibot S., Marechal V. (2011) Emergence of autoantibodies to HMGB1 is associated with survival in patients with septic shock. Intensive Care Med 37: 95762.
  • 54
    Schaer D.J., Schleiffenbaum B., Kurrer M., Imhof A., Bachli E., Fehr J., Moller H.J., Moestrup S.K., Schaffner A. (2005) Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol 74: 610.
  • 55
    Aristoteli L.P., Moller H.J., Bailey B., Moestrup S.K., Kritharides L. (2006) The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 184: 3427.
  • 56
    Moller H.J., Frikke-Schmidt R., Moestrup S.K., Nordestgaard B.G., Tybjaerg-Hansen A. (2011) Serum soluble CD163 predicts risk of type 2 diabetes in the general population. Clin Chem 57: 2917.
  • 57
    Moller H.J., Nielsen M.J., Bartram J., Dick M.C., Height S.E., Moestrup S.K., Rees D.C. (2011) Soluble CD163 concentrations in children with sickle cell disease. Br J Haematol 153: 10510.
  • 58
    Carrol E.D., Mankhambo L.A., Jeffers G., Parker D., Guiver M., Newland P., Banda D.L., Molyneux E.M., Heyderman R.S., Molyneux M.E., Hart C.A. (2009) The diagnostic and prognostic accuracy of five markers of serious bacterial infection in Malawian children with signs of severe infection. PLoS ONE 4: e6621.
  • 59
    Nomura S., Fujita S., Ozasa R., Nakanishi T., Miyaji M., Mori S., Ito T., Ishii K. (2011) The correlation between platelet activation markers and HMGB1 in patients with disseminated intravascular coagulation and hematologic malignancy. Platelets 22: 3967.
  • 60
    Yan X.X., Lu L., Peng W.H., Wang L.J., Zhang Q., Zhang R.Y., Chen Q.J., Shen W.F. (2009) Increased serum HMGB1 concentration is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205: 5448.
  • 61
    Shi Y., Sandoghchian Shotorbani S., Su Z., Liu Y., Tong J., Zheng D., Chen J., Liu Y., Xu Y., Jiao Z., Wang S., Lu L., Huang X., Xu H. (2012) Enhanced HMGB1 expression may contribute to Th17 cells activation in rheumatoid arthritis. Clin Dev Immunol 2012: 295 081.
  • 62
    Pavare J., Grope I., Kalnins I., Gardovska D. (2010) High-mobility group box-1 protein, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in children with community acquired infections and bacteraemia: a prospective study. BMC Infect Dis 10: 28.
  • 63
    Bruchfeld A., Wendt M., Bratt J., Qureshi A.R., Chavan S., Tracey K.J., Palmblad K., Gunnarsson I. (2011) High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med 17: 2935.
  • 64
    Ahn J.K., Cha H.S., Bae E.K., Lee J., Koh E.M. (2011) Extracellular high-mobility group box 1 is increased in patients with Behcet's disease with intestinal involvement. J Korean Med Sci 26: 697700.